Royce & Associates LP Travere Therapeutics, Inc. Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$7.18 - $9.82 $42,591 - $58,252
5,932 Added 14.25%
47,573 $366,000
Q4 2023

Feb 12, 2024
BUY
$5.44 - $9.5 $126,762 - $221,369
23,302 Added 127.06%
41,641 $374,000
Q3 2023

Nov 09, 2023
BUY
$7.64 - $17.25 $140,109 - $316,347
18,339 New
18,339 $163,000

Others Institutions Holding TVTX

# of Institutions
199
Shares Held
85M
Call Options Held
776K
Put Options Held
912K
View Full List

About Travere Therapeutics, Inc.

TVTX Quotes by TradingView
  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.36B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email